Common Injection Site Reactions with Bimzelx
Bimzelx (bimekizumab-bkzx), used for plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis, commonly causes local skin reactions at the injection site. These occur in about 20-23% of patients across clinical trials, typically mild to moderate and resolving without intervention.[1][2]
Patients most often report:
- Redness (erythema)
- Pain or tenderness
- Itching (pruritus)
- Swelling (edema)
- Bruising (ecchymosis)
- Hardening or nodules under the skin
These reactions usually appear within hours to days after the subcutaneous injection and decrease over time with continued use.[1]
How Often Do They Happen and How Long Do They Last?
In phase 3 trials (BE VIVID, BE READY, BE COMPLETE):
- Injection site reactions: 22% with Bimzelx vs. 7-14% with placebo or active comparators like adalimumab.
- Most were grade 1 (mild) or 2 (moderate); severe cases under 1%.[2][3]
Reactions peak in the first few doses but drop to under 5% incidence by month 3. They rarely lead to discontinuation (about 0.4% of patients).[1]
Why Do These Reactions Occur?
Bimzelx targets IL-17A and IL-17F, but reactions stem from the injection itself—common with biologics given subcutaneously every 4-8 weeks. Factors like injection technique, site rotation (abdomen, thigh, upper arm), or needle size influence severity. Warm compresses or antihistamines help mild cases; rotating sites prevents recurrence.[1][4]
What Should Patients Do If Reactions Worsen?
Mild symptoms need no treatment beyond monitoring. Seek medical help for:
- Signs of infection (pus, fever, increasing redness)
- Severe pain/swelling limiting movement
- Allergic symptoms like hives or breathing issues (rare anaphylaxis risk <0.1%).[1]
No increased risk of serious infections from sites alone, but monitor amid immunosuppression.[2]
How Does Bimzelx Compare to Other IL-17 Inhibitors?
| Drug | Injection Site Reaction Rate | Notes |
|------|------------------------------|-------|
| Bimzelx | 20-23% | Dual IL-17 blocker; higher but mostly mild |
| Cosentyx (secukinumab) | 13-15% | Single IL-17A; similar profile |
| Taltz (ixekizumab) | 18-20% | Single IL-17A; itching more prominent |
Bimzelx edges higher initially but matches long-term tolerability.[2][5]
Tips to Minimize Reactions
- Inject at room temperature after 30 minutes out of fridge.
- Use proper technique: clean skin, 45-90° angle, avoid scars/bruises.
- Alternate sites; apply ice pre/post if prone to swelling.
- Over-the-counter hydrocortisone or oral Benadryl for itching.[4]
[1]: Bimzelx Prescribing Information, UCB Pharma (FDA label, 2023). [https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761185s000lbl.pdf]
[2]: BE VIVID/BE READY trial data, Lancet (2021). [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00947-3/fulltext]
[3]: BE COMPLETE trial, Arthritis Rheumatol (2022).
[4]: American Academy of Dermatology patient guide on biologics. [https://www.aad.org/public/diseases/psoriasis/treatment/medications/biologics]
[5]: Cosentyx/Taltz labels via Drugs@FDA.